Jaguar Health To Present Phase 3 OnTarget Trial Results For Its Cancer Supportive Care Drug Crofelemer On Or Before July 23, 2024
Jaguar Health To Present Phase 3 OnTarget Trial Results For Its Cancer Supportive Care Drug Crofelemer On Or Before July 23, 2024
Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis
在7月23日或之前的投資者網絡研討會上，將更新Jaguar癌症支持治療組合的進展，包括Jaguar科學團隊、患者倡導者和腫瘤治療相關腹瀉（CTD）和口腔黏膜炎領域的領先腫瘤學專家的參與。
Cancer patients with diarrhea are 40% more likely to discontinue their therapy, and up to 40% of cancer patients experience the painful side effect of oral mucositis
患有腹瀉的癌症患者停止治療的可能性增加了40%，高達40%的癌症患者經歷口腔黏膜炎這種痛苦的副作用。
SAN FRANCISCO, CA / ACCESSWIRE / June 12, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it will hold an investor webcast on or before July 23, 2024 to provide results for the company's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy, with or without standard chemotherapy. The webcast, which will provide updates on Jaguar's advancing cancer supportive care portfolio, will include members of Jaguar's scientific team, patient advocates, and leading oncology experts on two of the most common and intolerable side effects of cancer therapy: CTD and oral mucositis.
加州舊金山，2024年6月12日/ACCESSWIRE/ - Jaguar Health, Inc.（納斯達克：jaguar health） 今天宣佈，將在2024年7月23日或之前舉行投資者網絡研討會，介紹兩種最常見和不可忍受的腫瘤治療副作用之一的CTD和口腔黏膜炎，在靶向治療或標準化學治療基礎上，提供Crofelemer用於治療固體腫瘤的III期研究OnTarget試驗的結果。在網絡研討會上，將介紹Jaguar公司的科學團隊、患者倡導者和腫瘤學領域的領先專家，以更新Jaguar不斷髮展的癌症支持治療組合。
譯文內容由第三人軟體翻譯。